Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Receivables (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Change in Receivables for 6 consecutive years, with -$2.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 273.58% year-over-year to -$2.7 million, compared with a TTM value of $10.6 million through Dec 2025, up 773.15%, and an annual FY2025 reading of $10.6 million, up 773.15% over the prior year.
  • Change in Receivables was -$2.7 million for Q4 2025 at Xeris Biopharma Holdings, down from $703000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $15.7 million in Q3 2023 and bottomed at -$6.8 million in Q4 2023.
  • Average Change in Receivables over 5 years is $2.0 million, with a median of $1.5 million recorded in 2021.
  • Peak annual rise in Change in Receivables hit 891.5% in 2024, while the deepest fall reached 6043.33% in 2024.
  • Year by year, Change in Receivables stood at -$449000.0 in 2021, then surged by 837.64% to $3.3 million in 2022, then tumbled by 304.38% to -$6.8 million in 2023, then soared by 89.32% to -$723000.0 in 2024, then crashed by 273.58% to -$2.7 million in 2025.
  • Business Quant data shows Change in Receivables for XERS at -$2.7 million in Q4 2025, $703000.0 in Q3 2025, and $6.7 million in Q2 2025.